title: Markers of inflammation after zoledronic acid redosing.
abstract: The symptoms of acute phase response (APR) following the first infusion of zoledronic acid (ZA) are attenuated after re-administration. We investigated the reasons for this attenuation, focusing on the changes in several hormones, bone markers and markers of inflammation occurring after the second ZA injection in patients who had experienced a severe APR after their first ZA infusion. Twenty-two postmenopausal women with osteoporosis and severe symptoms of APR following the first ZA infusion were included in the study (group A1). A year later, the same women (possibly with a residual activity of ZA) were subjected to ZA re-administration (group A2). Urine NTx (uNTx), white blood cells, parathyroid hormone, serum calcium, phosphorus and several serum markers of inflammation were measured before (0) and at 1 and 2 days following the first as well as the second infusion. In group A1, the APR was associated with a significant increase in serum C-reactive protein (CRP), high-sensitive interleukin 6 (hsIL-6), high-sensitive tumor necrosis factor alpha (hsTNF-α) and cortisol within 24 h after the infusion. The majority of the patients in group A2 did not experience an APR and serum calcium, phosphorus, CRP, hsIL-6, hsTNF-α, and cortisol remained essentially unchanged throughout the study. In group A2, on day 0, the uNTx were significantly lower than in group A1. In group A1 the uNTx decreased by 69 and 78% from baseline on days 1 and 2, whereas in group A2, they decreased by 48 and 53% (p < 0.01), respectively. A positive correlation was found between the degree of uNTx decline from the baseline levels (Δ-uNTx) and hsTNF-α and between Δ-uNTx and CRP. The Δ-uNTx, reflecting the osteoclast-mediated bone resorption, may play some role in the APR appearance, although it must be excluded if the relationships of the changes between uNTx and hsTNF-α/CRP are coincidental effects and not causal.
authors.affiliation: Second Division of Endocrinology, Alexandra Hospital, Vas. Sofias and Lourou str, Athens, Greece.
authors.forename: Antonis
authors.initials: A
authors.lastname: Sykiotis
authors.forename: Garyphallia
authors.initials: G
authors.lastname: Papaioannou
authors.forename: Jordan
authors.initials: J
authors.lastname: Mavropoulos
authors.forename: Maria
authors.initials: M
authors.lastname: Triantaphyllopoulou
authors.forename: Fotini
authors.initials: F
authors.lastname: Papandroulaki
authors.forename: Vassiliki
authors.initials: V
authors.lastname: Ktena
authors.forename: Stavroula
authors.initials: S
authors.lastname: Thanou
authors.forename: Argyris
authors.initials: A
authors.lastname: Pardalakis
authors.forename: Aikaterini
authors.initials: A
authors.lastname: Kaltsa
authors.forename: Helen
authors.initials: H
authors.lastname: Karga
mesh_terms: D015415:Biomarkers / Q000097:blood*; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use*; D004164:Diphosphonates / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use*; D007249:Inflammation / Q000097:blood*; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000097:blood / Q000188:drug therapy; D012044:Regression Analysis; D000077211:Zoledronic Acid
chemical_list: D015415:Biomarkers; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid